Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK101 in Moderate-to-Severe Plaque Psoriasis (China, Phase 3)
CTR20212660Phase 3Completed
- Sponsor
- Akeso, Inc.
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ebdarokimab in plaque psoriasis, sponsored by Akeso, Inc.. Started Oct 2021; status: completed.
02
Drugs
ebdarokimab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20212660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212660.